An age-related decrease in factor V Leiden frequency among Polish subjects

• Autorzy: Adler G. , Parczewski M. , Czerska E. , Loniewska B. , Kaczmarczyk M. , Gumprecht J. , Grzeszczak W. , Szybinska A. , Mossakowska M. , Ciechanowicz A.
• Języki publikacji: EN

Abstrakty

EN

Factor V Leiden (G1691A FV mutation) is a widely acknowledged risk factor of deep vein thrombosis, including pulmonary embolism as the most serious complication. However, its high prevalence of ~5% in the Caucasian population might be related to an unknown evolutionary advantage. It might exert a beneficial effect on the carrier, e.g. protecting women from excessive bleeding during labour or allowing increased survival in severe sepsis or with other inflammatory diseases. The aim of our study was to verify or contradict the hypothesis of a favourable association between the A allele (A1691) and longevity in the Polish population. For this purpose, the G1691A mutation was analyzed by PCR-RFLP in 1016 Poles: 400 neonates (187 female and 312 male), 184 healthy adults (129 female and 55 male), and 432 long-lived individuals (age ≥ 95 years: 343 women and 89 men). Frequencies of G1691A carriers and the A1691 allele in long-lived individuals (0.2% and 0.1%, respectively) were significantly lower than in neonates (4.2% and 2.2%, respectively) and adults (3.3% and 1.6%). The frequency of the G1691A factor V Leiden mutation decreased with age, which indicates a shorter survival time among A1691 allele carriers in the Polish population.

Słowa kluczowe

EN

factor V Leiden; risk factor; thrombosis; prevalence; animal disease; woman; inflammatory disease; Polish population; Leiden Factor 5 zob.factor V Leiden

• Wydawca: -
• Czasopismo: Journal of Applied Genetics
• Rocznik: 2010
• Tom: 51
• Numer: 3
• Opis fizyczny: p.337-341,ref.

Twórcy

autor

Adler G.

• Department of Laboratory Diagnostics and Molecular Medicine, Pomeranian Medical University, Powstancow Wlkp.72, 70-111 Szczecin

autor

Parczewski M.

• Department of Infectious Diseases and Hepatology, Pomeranian Medical University, Szczecin, Poland

autor

Czerska E.

• "MEDIS" Laboratory, Public Clinical Hospital No. 1, Pomeranian Medical University, Szczecin, Poland

autor

Loniewska B.

• Department of Neonatology, Pomeranian Medical University, Szczecin, Poland

autor

Kaczmarczyk M.

• Department of Laboratory Diagnostics and Molecular Medicine, Pomeranian Medical University, Powstancow Wlkp.72, 70-111 Szczecin

autor

Gumprecht J.

• Department and Clinic of Internal Medicine, Diabetology and Nephrology, Silesian University of Medicine, Zabrze, Poland

autor

Grzeszczak W.

• Department and Clinic of Internal Medicine, Diabetology and Nephrology, Silesian University of Medicine, Zabrze, Poland

autor

Szybinska A.

• International Institute of Molecular and Cell Biology, Warszawa, Poland

autor

Mossakowska M.

• International Institute of Molecular and Cell Biology, Warszawa, Poland

autor

Ciechanowicz A.

• Department of Laboratory Diagnostics and Molecular Medicine, Pomeranian Medical University, Powstancow Wlkp.72, 70-111 Szczecin

Bibliografia

• Andre E, Siguret V, Alhenc- Gelas M, Saint-Jean, Gaussem P, 1998. Venous thrombosis in older people: prevalence of the factor V gene mutation Q506. J Am Geriatr Soc 46: 1545- 1549.
• Andrew M, David M, Adams M, Kaiser A, Anderson R, Barnard D, et al. 1994. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian registry of VTE. Blood. 83: 1251-1257.
• Aronis S, Bonza H, Perqanton H. et al. 2002. Prothrombolic factor of neonates with cerebral thrombosis and intraventricular hemorrhage. Acta Pediatr Suppl 91: 87-91.
• Atasay B, Arsan S, Gunlemez A, 2003. Factor V Leiden and prothrombin gene 20210A variant in neonatal thromboembolism and in healthy neonates and adults: a studv in a single center. Pediatr Hematol Oncol 20: 627-634.
• Conroy JM, Trivedi G, Sovd T. Caggana M, 2000. The allele frequency of mutations in four genes that confer enhanced susceptibility to venous thromboembolism in an unselected group of New York State newborns. Thromb Res 99: 317-324.
• Cybulski C, Wokolorczyk D, Huzarski T, Byrski T, Gronwald J, Górski B, et al. 2006. A large germline deletion in the Chek 2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet 43: 863-866.
• Dahlbäck B, 1996. Are we ready for factor V Leiden screening? Lancet 347: 1346-1347.
• Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, et al. 2001. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism. Pooled analysis of 8 case-control studies, including 2310 cases and 3204 controls. Thromb Haemost 86: 809-816
• Faure-Delanef L, Quere I, Zouali H, Cohen D, 1997. Human longevity and R506Q factor V gene mutation. Thromb Haemost 78: 1160.
• Gandrille S, Alhenc-Gelas M, Aiach M, 1995. A rapid screening method for the factor V Arg 506﹥Gln mutation. Blood Coagul Fibrynolysis. 6: 245-247.
• Hartel C, Konig I, Koster S, Kattner E, Kuhls E, Kuster H, et al. 2006. Genetic polymorphisms of hemostasis genes and primary outcome of very low birth weight infants. Pediatries 118: 683-689.
• Herrmann FH, Koesling M, Schroder W, Altman R, Jiménez Bonilla R, Lopaciuk S, et al. 1997. Prevalence of factor V Leiden mutation in various populations. Genet Epidemiol 14: 403-411.
• Johanson CH, Hyland V, Wicking C, Sturm RA, 2009. DNA elution from buccal cells stored on Whatman FTA Classic Cards using a modified methanol fixation method. Biotechniques. 46: 309-311.
• Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, et al. 2003. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endoxemia. Blood. 102: 3085-3091.
• Kodaira H, Ishida F, Shimodaira S, Takamiya O, Furihata K, Kitano K, 1997. Resistance to activated protein C and Arg506Gln factor V mutation are uncommon in eastern Asian populations. Acta Haematol. 98: 22-25.
• Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM, 1993. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 342: 1503-1506.
• Kristensen SR, Andersen-Ranberg K, Bathum L, Jeune B, 1998. Factor V Leiden and venous thrombosis in Danish centenarians. Thromb Haemost. 80: 860-861.
• Larsen TB, Lassen JF, Brandslund I, Prtersen GB, Norgaard-Pedersen B, 1998. The arg506gln mutation (FV- Leiden) among a cohort of 4188 unselected Danish newborns. Thromb Res 89: 211-215.
• Lindqvist PG, Dahlbäck B, 2008. Carriership of Factor V Leiden and evolutionary selection advantage. Curr Med Chem 15: 1541-1544.
• MacNerlan SE, Crawford VLS, Stout RW, 1997. Factor V Leiden in a healthy Northern Ireland elderly population. Age Ageing 26: 408- 409.
• Mari D, Manucci PM, Duca F, Bertolini S, Franceschi C, 1996. Mutant factor V (Arg506Gln) in healthy centenarians. Lancet 347: 1044.
• Mossakowska M, Barcikowska M, Broczek K, Grodzicki T, Klich-Raczka A, Kupisz-Urbanska M, et al. 2008. Polish Centenarians Programme - multidisciplinary studies of successful ageing: Aims, methods, and preliminary results. Exp Gerontol. 43: 238-244.
• Rees DC, Cox M, Clegg JB, 1995. World distribution of factor V Leiden. Lancet 346: 1133-1134.
• Rees DC, Liu YT, Cox MJ, Elliott P, Wainscoat JS, 1997. Factor V Leiden and thermolabile methylenetetrahydrofolate reductase in extreme old age. Thromb Haemost 78: 1357-1359.
• Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP, 1995. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 332: 912-917.
• Rosendaal FR, 1997. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost 78: 1-6.
• Rosendorff A, Dorfman DM, 2007. Activated protein C resistance and factor V Leiden: a review. Arch Pathol Lab Med 131: 866-871.
• Schambeck CM, Schwender S, Haubitz I, 1997. Selective screening for the factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives? Thromb Haemost 78: 1480-1483.
• Sipahi T, Pocan H, Akar N, 2006. Clin Appl Thromb Hemost. 12: 47-54.
• van't Veer C, Golden NJ, Kalafatis M, Simoni P, Bertina RM, Mann KG, 1997. An in vitro analysis of the combination of factor V Leiden and hemophilia A. Blood. 90: 3067-3072.
• Zivelin A, Griffin JH, Xu X, Pabinger I, Samama M, Conard J, et al. 1997. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood. 89: 397-402.